Halozyme Therapeutics Inc (NASDAQ:HALO) shares, rose in value on Friday, November 22, with the stock price up by 5.70% to the previous day’s close as strong demand from buyers drove the stock to $48.31.
Actively observing the price movement in the recent trading, the stock is buoying the session at $45.70, falling within a range of $46.3 and $49.194. The value of beta (5-year monthly) is 1.29 whereas the PE ratio is 15.98 over 12-month period. Referring to stock’s 52-week performance, its high was $65.53, and the low was $33.15. On the whole, HALO has fluctuated by -2.02% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With the market capitalization of Halozyme Therapeutics Inc currently standing at about $6.15 billion, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that HALO’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0.55, with the price of HALO currently trading nearly -9.19% and -11.48% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.56, while the 7-day volatility ratio is showing 6.30% which for the 30-day chart, stands at 4.63%. Furthermore, Halozyme Therapeutics Inc (HALO)’s beta value is 1.23, and its average true range (ATR) is 2.75.
A comparison of Halozyme Therapeutics Inc (HALO) with its peers suggests the former has fared considerably weaker in the market. HALO showed an intraday change of 5.70% in today’s session so far, and over the past year, it grew by 20.43%%.
Data on historical trading for Halozyme Therapeutics Inc (NASDAQ:HALO) indicates that the trading volumes over the past 10 days have averaged 2.78 and over the past 3 months, they’ve averaged 1.58 million. According to company’s latest data on outstanding shares, there are 126.77 million shares outstanding.
Nearly 1.08% of Halozyme Therapeutics Inc’s shares belong to company insiders and institutional investors own 99.29% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.25 million shares as on 2024-10-31, resulting in a short ratio of 7.75. According to the data, the short interest in Halozyme Therapeutics Inc (HALO) stood at 1090.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 9.85 million. The stock has risen by 30.70% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HALO stock heading into the next quarter.
